Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Chemokine Therapeutics has reached an agreement to supply its investigational compound, CTCE-9908, to the National Cancer Institute, so that its potential in a rare form of cancer can be evaluated.
Subscribe to our email newsletter
The researchers at the NCI will investigate the role of CTCE-9908 in the pathology of primary effusion lymphoma (PEL), a rare form of non-Hodgkin lymphoma that is usually associated with human immunodeficiency virus infections (HIV).
This aggressive type of lymphoma presents primarily in advance-stage HIV-infected individuals whose disease grows and spreads primarily in the body cavity. In patients, the clinical course for this disease is often aggressive, more extensive, and less responsive to chemotherapy.
The new agreement with the NCI marks the first exploration of a series of preclinical studies in a lymphoma cell line, the results of which will help direct future strategies in clinical trials.
CTCE-9908 has shown promising results against several cancer types in preclinical models including lung, prostate and bone cancers.